Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

1.

Pioglitazone has anti-inflammatory effects in patients with Type 2 diabetes.

Heliövaara MK, Herz M, Teppo AM, Leinonen E, Ebeling P.

J Endocrinol Invest. 2007 Apr;30(4):292-7.

PMID:
17556865
[PubMed - indexed for MEDLINE]
2.

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Group.

N Engl J Med. 2007 Jul 5;357(1):28-38. Epub 2007 Jun 5.

PMID:
17551159
[PubMed - indexed for MEDLINE]
Free Article
3.

Effects of pioglitazone hydrochloride on Japanese patients with type 2 diabetes mellitus.

Teramoto T, Yamada N, Shirai K, Saito Y.

J Atheroscler Thromb. 2007 Apr;14(2):86-93.

PMID:
17485893
[PubMed - indexed for MEDLINE]
Free Article
4.

A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes.

Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RA.

Am Heart J. 2007 Mar;153(3):445.e1-6.

PMID:
17307426
[PubMed - indexed for MEDLINE]
5.

A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes.

Hanefeld M, Patwardhan R, Jones NP; Rosiglitazone Clinical Trials Study Group.

Nutr Metab Cardiovasc Dis. 2007 Jan;17(1):13-23. Epub 2006 Mar 20.

PMID:
17174222
[PubMed - indexed for MEDLINE]
6.

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group.

N Engl J Med. 2006 Dec 7;355(23):2427-43. Epub 2006 Dec 4. Erratum in: N Engl J Med. 2007 Mar 29;356(13):1387-8.

PMID:
17145742
[PubMed - indexed for MEDLINE]
Free Article
7.

Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.

Sharma PK, Bhansali A, Sialy R, Malhotra S, Pandhi P.

Clin Endocrinol (Oxf). 2006 Dec;65(6):722-8.

PMID:
17121522
[PubMed - indexed for MEDLINE]
8.

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.

Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB Sr, Perez A, Provost JC, Haffner SM.

JAMA. 2006 Dec 6;296(21):2572-81. Epub 2006 Nov 13.

PMID:
17101640
[PubMed - indexed for MEDLINE]
9.

Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus.

Jain R, Osei K, Kupfer S, Perez AT, Zhang J.

Pharmacotherapy. 2006 Oct;26(10):1388-95.

PMID:
16999648
[PubMed - indexed for MEDLINE]
10.

Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study.

Goldstein BJ, Weissman PN, Wooddell MJ, Waterhouse BR, Cobitz AR.

Curr Med Res Opin. 2006 Sep;22(9):1715-23.

PMID:
16968575
[PubMed - indexed for MEDLINE]
11.

Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria.

Bakris GL, Ruilope LM, McMorn SO, Weston WM, Heise MA, Freed MI, Porter LE.

J Hypertens. 2006 Oct;24(10):2047-55.

PMID:
16957566
[PubMed - indexed for MEDLINE]
12.
13.
14.

Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes.

Basu A, Jensen MD, McCann F, Mukhopadhyay D, Joyner MJ, Rizza RA.

Diabetes Care. 2006 Mar;29(3):510-4.

PMID:
16505497
[PubMed - indexed for MEDLINE]
15.

Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes.

Perriello G, Pampanelli S, Di Pietro C, Brunetti P; Italian Pioglitazone Study Group.

Diabet Med. 2006 Mar;23(3):246-52.

PMID:
16492206
[PubMed - indexed for MEDLINE]
16.

Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial.

Derosa G, Gaddi AV, Piccinni MN, Salvadeo S, Ciccarelli L, Fogari E, Ghelfi M, Ferrari I, Cicero AF.

Diabetes Obes Metab. 2006 Mar;8(2):197-205.

PMID:
16448524
[PubMed - indexed for MEDLINE]
17.

Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy.

Garber A, Klein E, Bruce S, Sankoh S, Mohideen P.

Diabetes Obes Metab. 2006 Mar;8(2):156-63.

PMID:
16448519
[PubMed - indexed for MEDLINE]
18.

Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2.

Forst T, Lübben G, Hohberg C, Kann P, Sachara C, Gottschall V, Friedrich C, Rosskopf R, Pfützner A.

Microcirculation. 2005 Oct-Nov;12(7):543-50.

PMID:
16207627
[PubMed - indexed for MEDLINE]
19.

Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control.

Pfützner A, Hohberg C, Lübben G, Pahler S, Pfützner AH, Kann P, Forst T.

Horm Metab Res. 2005 Aug;37(8):510-5.

PMID:
16138265
[PubMed - indexed for MEDLINE]
20.

Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes.

Yamanouchi T, Sakai T, Igarashi K, Ichiyanagi K, Watanabe H, Kawasaki T.

Diabet Med. 2005 Aug;22(8):980-5.

PMID:
16026361
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk